Julia Lai‐Kwon - Concepedia

Author

Julia Lai‐Kwon

Peter MacCallum Cancer Centre ORCID

Also Known As

J. Lai-Kwon, J. Lai‐Kwon, J.E. Lai-Kwon, Julia E Lai-Kwon, Julia Lai Kwon, Julia Lai-Kwon, Julia Lai‐Kwon

Publications

807

Citations

H-Index

Concepts

All Affiliations

Peter MacCallum Cancer Centre The University of Melbourne The University of Sydney Melanoma Institute Australia Institute of Cancer Research

About

Julia Lai‐Kwon is an author at Peter MacCallum Cancer Centre specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	204
2	Health Sciences	1	1	13
3	Public Health	1	1	21
4	Allergy	1	1	21
5	Emergency Medicine	1	1	21

Julia Lai‐Kwon

Publications

646

Citations

H-Index

Page 1

	Year	Citations
Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling Ismael A. Vergara, Christopher Mintoff, Shahneen Sandhu, Nature Communications	2021	73
Evolving Landscape of Metastatic Cancer Survivorship: Reconsidering Clinical Care, Policy, and Research Priorities for the Modern Era Julia Lai‐Kwon, Sarah Heynemann, Nicolas H. Hart, Journal of Clinical Oncology	2023	47
Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy Julia Lai‐Kwon, Sarah Heynemann, Jacinthe Flore, Journal of Cancer Survivorship MedicineCancer ManagementImmunologyImmune Checkpoint InhibitorSurvivorship Experience	2021	46
The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors Julia Lai‐Kwon, Chloe Khoo, Serigne Lo, Journal of Cancer Survivorship Immune CheckpointMedicineCancer ManagementMelanomaImmunology	2019	45
CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience Arvind Sahu, Michael Jefford, Julia Lai‐Kwon, Journal of Oncology	2019	43
Implementing novel models of posttreatment care for cancer survivors: Enablers, challenges and recommendations Michael Jefford, Nicole Kinnane, Paula Howell, Asia-Pacific Journal of Clinical Oncology	2015	40
Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma Fiona Lynch, Lynda Katona, Michael Jefford, Journal of Clinical Medicine	2020	37
Efficacy of immune checkpoint inhibitors for in-transit melanoma Emilia Nan Tie, Julia Lai‐Kwon, Michael Rtshiladze, Journal for ImmunoTherapy of Cancer	2020	35
Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer Richard D. Baird, Mafalda Oliveira, Eva María Ciruelos Gil, Cancer Research Breast OncologyOncologyOngoing Phase 1Cancer ManagementPharmacology	2021	32
Trends in patient‐reported outcome use in early phase dose‐finding oncology trials – an analysis of ClinicalTrials.gov Julia Lai‐Kwon, Zhulin Yin, Anna Minchom, Cancer Medicine	2021	30

Page 1